MCM
SRPT icon

Murphy Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Murphy Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-5,700
Closed -$269K – 330
2013
Q3 		$269K Sell
5,700
-400
-7% -$15.4K 0.05% 258
2013
Q2 		$232K Buy
+6,100
New +$218K 0.05% 262

Other funds holding SRPT

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Murphy Capital Management's SRPT Position: Q4 2013 in Review

Murphy Capital Management sold out of Sarepta Therapeutics (SRPT) in Q4 2013, closing a stake of 5,700 shares — an estimated $269K sold.

Murphy Capital Management first reported a position in SRPT in Q2 2013 and held it in 2 quarters. The position peaked at $269K in Q3 2013. 108 funds tracked by Wall St. Rank hold SRPT as of Q4 2013.

  • Murphy Capital Management reported no remaining Sarepta Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Murphy Capital Management sold 5,700 Sarepta Therapeutics shares in Q4 2013, an estimated $269K.
  • Murphy Capital Management first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 2 quarters.
  • Murphy Capital Management's Sarepta Therapeutics position peaked at $269K in Q3 2013.
  • 108 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2013.

Based on Murphy Capital Management's 13F filing for Q4 2013, filed 10 Jan 2014.